← Search & browse all drugs

technetium (99mTc) furifosmin

V09GA05

Forms & Strengths

Kit for the preparation of technetium Tc 99m furifosmin injection

Adult Dosing

Diagnostic intravenous administration: 370 to 1110 MBq (10 to 30 mCi) depending on the specific imaging protocol and equipment used

Pediatric Dosing

Safety and effectiveness in pediatric patients have not been established

Indications

Radiopharmaceutical diagnostic agent indicated for myocardial perfusion imaging to evaluate coronary artery disease

Mechanism of Action

Lipophilic cationic technetium-99m complex that passively diffuses into myocardial cells proportional to coronary blood flow and is retained intracellularly via mitochondrial binding

Contraindications

Known hypersensitivity to technetium Tc 99m furifosmin or any of its components
Pregnancy and lactation, unless the diagnostic benefit outweighs potential risks

Adverse Reactions

Generally well-tolerated with a low incidence of adverse effects
Rare reports of transient headache, flushing, metallic taste, nausea, or injection site discomfort
Hypersensitivity reactions rarely observed

Drug Interactions

Drugs that alter myocardial perfusion (e.g., calcium channel blockers, beta-blockers, nitrates, dipyridamole) may affect the diagnostic utility of myocardial imaging
No specific pharmacokinetic drug-drug interactions of clinical significance have been formally established

Curated Content: Needs Vetting Before Put to Clinical Use